EXAMINING THE COMPARATIVE EFFECTIVENESS AND SAFETY OF TOPIRAMATE AND LAMOTRIGINE MONOTHERAPY IN THE TREATMENT OF MIGRAINE

Abstract

The comparative research was conducted from retrospective viewpoint and the results were discussed in accordance with the best efficiency and certainty of topiramate monotherapy vs lamotrigine monotherapy in the migraine treatment using the individual medical records of 500 patients who suffered from migraine. There were 250 of patients who had topiramate and 250 who had lamotrigine. The groups were homogeneous in terms of the baseline parameters. Specific treatment prescriptions were adhered to, with pre-set response rate and adverse event criteria as the basis for the comparisons of outcomes. In the case of epilepsy, long-term treatment, the remission rate for topiramate group was 75% and 70% for lamotrigine which indicated a relatively higher efficacy in topiramate. But there was no dose differing adverse events between group with 20% of topiramate trial subjects and 18% of lamotrigine trial participant reported the incidence. The statistics showed a significant difference between the response rates of the topiramate in favor of topiramate (p=0.045), but the statistics did not show a significant difference in adverse events (p=0.320). A summation of the outcomes, topiramate exhibited a superior migraine treatment efficacy compared to lamotrigine monotherapy, in spite of both drugs having an equivalent level of tolerability. There was a nearly comparable adverse event occurrence. The decision of medical professionals when it comes to selecting the most suitable single therapy option between different migraine medications, should be based on the disease profile as well as patient factors.